Literature DB >> 32660982

Occupational and environmental risk factors for idiopathic pulmonary fibrosis in Australia: case-control study.

Michael J Abramson1, Tsitsi Murambadoro2, Sheikh M Alif2, Geza P Benke2, Shyamali C Dharmage3, Ian Glaspole4, Peter Hopkins5,6, Ryan F Hoy2, Sonja Klebe7, Yuben Moodley8,9, Shuli Rawson2, Paul N Reynolds10, Rory Wolfe2, Tamera J Corte11, E Haydn Walters12.   

Abstract

INTRODUCTION: Idiopathic pulmonary fibrosis (IPF) is a lung disease of unknown cause characterised by progressive scarring, with limited effective treatment and a median survival of only 2-3 years. Our aim was to identify potential occupational and environmental exposures associated with IPF in Australia.
METHODS: Cases were recruited by the Australian IPF registry. Population-based controls were recruited by random digit dialling, frequency matched on age, sex and state. Participants completed a questionnaire on demographics, smoking, family history, environmental and occupational exposures. Occupational exposure assessment was undertaken with the Finnish Job Exposure Matrix and Australian asbestos JEM. Multivariable logistic regression was used to describe associations with IPF as ORs and 95% CIs, adjusted for age, sex, state and smoking.
RESULTS: We recruited 503 cases (mean±SD age 71±9 years, 69% male) and 902 controls (71±8 years, 69% male). Ever smoking tobacco was associated with increased risk of IPF: OR 2.20 (95% CI 1.74 to 2.79), but ever using marijuana with reduced risk after adjusting for tobacco: 0.51 (0.33 to 0.78). A family history of pulmonary fibrosis was associated with 12.6-fold (6.52 to 24.2) increased risk of IPF. Occupational exposures to secondhand smoke (OR 2.1; 1.2 to 3.7), respirable dust (OR 1.38; 1.04 to 1.82) and asbestos (OR 1.57; 1.15 to 2.15) were independently associated with increased risk of IPF. However occupational exposures to other specific organic, mineral or metal dusts were not associated with IPF.
CONCLUSION: The burden of IPF could be reduced by intensified tobacco control, occupational dust control measures and elimination of asbestos at work. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  asbestos induced lung disease; idiopathic pulmonary fibrosis; occupational lung disease; tobacco and the lung

Mesh:

Substances:

Year:  2020        PMID: 32660982     DOI: 10.1136/thoraxjnl-2019-214478

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  10 in total

1.  Occupational exposures and IPF: when the dust unsettles.

Authors:  Cathryn T Lee; Kerri A Johannson
Journal:  Thorax       Date:  2020-09-08       Impact factor: 9.139

2.  Efficacy of dental evacuation systems for aerosol exposure mitigation in dental clinic settings.

Authors:  Brie Hawley Blackley; Kimberly R Anderson; Fotinos Panagakos; Tammy Chipps; M Abbas Virji
Journal:  J Occup Environ Hyg       Date:  2022-04-06       Impact factor: 3.359

Review 3.  Identification and Remediation of Environmental Exposures in Patients With Interstitial Lung Disease: Evidence Review and Practical Considerations.

Authors:  Carla R Copeland; Bridget F Collins; Margaret L Salisbury
Journal:  Chest       Date:  2021-02-18       Impact factor: 10.262

4.  Inhalational exposures in patients with fibrotic interstitial lung disease: Presentation, pulmonary function and survival in the Canadian Registry for Pulmonary Fibrosis.

Authors:  Cathryn T Lee; Mary E Strek; Ayodeji Adegunsoye; Alyson W Wong; Deborah Assayag; Gerard Cox; Charlene D Fell; Jolene H Fisher; Andrea S Gershon; Andrew J Halayko; Nathan Hambly; Nasreen Khalil; Martin Kolb; Stacey D Lok; Hélène Manganas; Veronica Marcoux; Julie Morisset; Mohsen Sadatsafavi; Shane Shapera; Teresa To; Pearce Wilcox; Christopher J Ryerson; Kerri A Johannson
Journal:  Respirology       Date:  2022-05-05       Impact factor: 6.175

Review 5.  TGF‑β1: Gentlemanly orchestrator in idiopathic pulmonary fibrosis (Review).

Authors:  Zhimin Ye; Yongbin Hu
Journal:  Int J Mol Med       Date:  2021-05-20       Impact factor: 4.101

Review 6.  COVID-19 and pulmonary fibrosis: A potential role for lung epithelial cells and fibroblasts.

Authors:  Alison E John; Chitra Joseph; Gisli Jenkins; Amanda L Tatler
Journal:  Immunol Rev       Date:  2021-05-24       Impact factor: 10.983

7.  Effect of home-based pulmonary rehabilitation on functional capacity in people with idiopathic pulmonary fibrosis-a systematic review protocol.

Authors:  Revati Amin; K Vaishali; G Arun Maiya; Aswini Kumar Mohapatra; Uday Narayan Yadav; Shradha S Parsekar
Journal:  Syst Rev       Date:  2021-11-15

8.  Network Pharmacology Prediction and Molecular Docking-Based Strategy to Discover the Potential Pharmacological Mechanism of Wen-Yu-Jin against Pulmonary Fibrosis in a Mouse Model.

Authors:  Lu Wang; Wenxiang Zhu; Rui Sun; Jing Liu; Qihong Ma; Binbin Zhang; Yuanyuan Shi
Journal:  Evid Based Complement Alternat Med       Date:  2022-02-10       Impact factor: 2.629

9.  Demystifying pulmonary fibrosis.

Authors:  Gisli Jenkins
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-08-05       Impact factor: 5.464

10.  Clinical characteristics and outcomes of post-COVID-19 pulmonary fibrosis: A case-control study.

Authors:  Shereen Farghaly; Mohammed Badedi; Rehab Ibrahim; Murad H Sadhan; Aymn Alamoudi; Awaji Alnami; Abdulrahman Muhajir
Journal:  Medicine (Baltimore)       Date:  2022-01-21       Impact factor: 1.889

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.